Old Mission Capital’s Immunic IMUX Stock Holding History

Old Mission Capital’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,697	Closed	-$259K	–	803
2020 Q4	$259K	Buy	+1,697	New	+$305K	0.02%	463

Other funds holding IMUX

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Old Mission Capital's IMUX Position: Q1 2021 in Review

Old Mission Capital sold out of Immunic (IMUX) in Q1 2021, closing a stake of 1,697 shares — an estimated $259K sold.

Old Mission Capital first reported a position in IMUX in Q4 2020 and held it in 1 quarter. The position peaked at $259K in Q4 2020. 63 funds tracked by Wall St. Rank hold IMUX as of Q1 2021.

Old Mission Capital reported no remaining Immunic position as of Q1 2021 after selling out during the quarter.
Old Mission Capital sold 1,697 Immunic shares in Q1 2021, an estimated $259K.
Old Mission Capital first reported a position in Immunic in Q4 2020 and held it in 1 quarter.
Old Mission Capital's Immunic position peaked at $259K in Q4 2020.
63 funds tracked by Wall St. Rank held Immunic as of Q1 2021.

Based on Old Mission Capital's 13F filing for Q1 2021, filed 14 May 2021.